Relief Therapeutics Holding SA, a biopharmaceutical company, announces that its collaboration partner, ACER Therapeutics, Inc., has provided an update on commercial launch activities for Olpruva.
Relief Therapeutics entered a collaboration and license agreement with Acer Therapeutics Inc. in March 2021 for the worldwide development and commercialization of Olpruva (sodium phenylbutyrate; ACER-001) for oral suspension for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and maple syrup urine disease (MSUD).
Acer reports that in support of the Olpruva launch in Q2 2023, the company is actively adding resources to establish its commercial and medical affairs presence in the US. As a part of its Olpruva commercialization strategy, Acer has recently introduced its patient support service, Olpruva Navigator by Acer Therapeutics, designed to assist UCD patients with support, access, education and patient adherence to treatment. Representatives will begin accepting prescriptions in late Q2 2023. Acer also reports the company is actively engaged in negotiations regarding access for Olpruva with the major commercial payers and state Medicaid organizations.
According to Acer, the company has established a pricing strategy that reflects its commitment to deliver innovative treatments that are responsibly priced and accessible to those in need. Acer intends to price Olpruva competitively, at a significant discount to the currently available commercial product Ravicti, while implementing predictable pricing that will not increase beyond the rate of inflation. Acer indicated the company also plans to invest a portion of Olpruva revenue back into additional solutions aimed at improving outcomes for UCD patients.
